Back to Search
Start Over
Dual inhibition of mTOR pathway and VEGF signalling in neuroendocrine neoplasms: from bench to bedside.
Dual inhibition of mTOR pathway and VEGF signalling in neuroendocrine neoplasms: from bench to bedside.
- Source :
-
Cancer treatment reviews [Cancer Treat Rev] 2015 Nov; Vol. 41 (9), pp. 754-60. Date of Electronic Publication: 2015 Jun 28. - Publication Year :
- 2015
-
Abstract
- After years of limited progress in the treatment of neuroendocrine neoplasms (NENs), an increasing number of therapeutic targets have recently emerged as potential tools to improve disease outcome. The mammalian target of rapamycin (mTOR) pathway and vascular endothelial growth factor (VEGF) signalling are implicated in the regulation of cell growth, proliferation, neo-angiogenesis and tumour cell spread. Their combined blockade, in a simultaneous or sequential strategy, represents an intriguing biological rationale to overcome the onset of resistance mechanisms. However, is becoming increasingly imperative to find the optimal sequential strategy according to the best toxicity profile, and also to identify predictive biomarkers. We will provide an overview of the pre-clinical and clinical data relating to mTOR pathway/VEGF signalling as a potential targets of treatment in NENs.<br /> (Copyright © 2015 Elsevier Ltd. All rights reserved.)
- Subjects :
- Angiogenesis Inducing Agents administration & dosage
Animals
Clinical Trials as Topic
Drug Synergism
Humans
Indoles administration & dosage
Indoles pharmacology
Molecular Targeted Therapy
Neuroendocrine Tumors metabolism
Protein Kinase Inhibitors administration & dosage
Pyrroles administration & dosage
Pyrroles pharmacology
Signal Transduction drug effects
Sunitinib
TOR Serine-Threonine Kinases metabolism
Translational Research, Biomedical
Vascular Endothelial Growth Factor A metabolism
Angiogenesis Inducing Agents pharmacology
Antineoplastic Combined Chemotherapy Protocols pharmacology
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Neuroendocrine Tumors drug therapy
Protein Kinase Inhibitors pharmacology
TOR Serine-Threonine Kinases antagonists & inhibitors
Vascular Endothelial Growth Factor A antagonists & inhibitors
Subjects
Details
- Language :
- English
- ISSN :
- 1532-1967
- Volume :
- 41
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Cancer treatment reviews
- Publication Type :
- Academic Journal
- Accession number :
- 26142874
- Full Text :
- https://doi.org/10.1016/j.ctrv.2015.06.008